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O estudo fitoquímico do invertebrado marinho Eudistoma vannamei levou ao isolamento de 
derivados do alcalóide estaurosporina, que apresentaram uma potente atividade citotóxica contra 
linhagens de células humanas de câncer. A ocorrência destes alcalóides pode ser correlacionada 
a presença de microorganismos associados ao animal, como por exemplo bactérias do gênero 
Streptomyces. Visando confirmar essa hipótese, precedeu-se o isolamento e cultivo dos 
microrganismos associados com E. vannamei (84 cepas isoladas). Estudos sistemáticos das 
reações de fragmentação da estaurosporina e derivados, apoiados pela química computacional, 
permitiram definir os principais padrões de fragmentação. Esses padrões foram utilizados em 
análises exploratórias por LC-MS/MS visando pesquisar a presença de derivados de estaurosporinas 
nos microrganismos isolados. Esse procedimento permitiu identificar estaurosporina em uma 
espécie de Streptomyces, contudo não com o mesmo padrão de oxidação da molécula ativa isolada 
no extrato da Ascídia. Finalmente, o extrato dessa cepa mostrou também significativa atividade 
citotóxica contra linhagens de câncer.
Former bioactivity-guided analysis of the marine invertebrate Eudistoma vannamei led to the 
isolation of staurosporine derivatives, which revealed strong cytotoxic activity against several 
human cancer cell lines. The occurrence of such alkaloids in E. vannamei may be correlated to 
the presence of associated biota, such as Streptomyces bacteria. In agreement to this hypothesis, 
marine microorganisms associated with E. vannamei were recovered and cultured, leading to a total 
of 84 isolated bacterial strains. Gas phase fragmentation reactions of staurosporine and derivatives 
were systematically studied and the analyzed results further supported by computational chemistry 
studies. The resulting fragment patterns were used to search for the presence of different derivatives 
in extracts of isolated microorganisms, thereby using LC-MS/MS analysis in MRM mode. These 
results evidenced that one isolated Streptomyces sp. was able to generate staurosporine, while 
none of the hydroxy-7-oxo derivatives were detected. Finally, significant cytotoxic activity against 
human cancer lines was observed for one of the extracts.
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Introduction
Historically, the search for bioactive marine natural 
products has been focused on invertebrate species such 
as sponges, ascidians and corals. However, different 
studies suggest that several natural products previously 
described for marine invertebrates are in fact secondary 
metabolites produced by microorganisms associated to 
these organisms.1,2 Eudistoma vannamei is a Brazilian 
endemic ascidian, whose extract was demonstrated as 
being highly cytotoxic against several human cancer cell 
lines.3 The bioactivity-guided fractionation of the ethanol 
extract from the respective ascidian species, suggested the 
presence of tryptophan derived compounds with strong 
cytotoxic activity against cancer cell lines.4 Further analysis 
of active fractions led to the identification of two novel 
alkaloids of the staurosporine type, namely 2-hydroxy-
7-oxo-staurosporine and 3-hydroxy-7-oxo-staurosporine 
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(Figure 1). Cytotoxicity experiments of the alkaloid mixture 
also revealed strong activity, exhibiting an IC50 value in the 
nanomolar potency.5
Staurosporine was first isolated in 1977 from 
Streptomyces staurisporeus and later also from other 
actinomycetes as well as cyanobacteria.6 In the meantime 
several staurosporine analogues were isolated from 
actinomycetes5 and also from marine invertebrate, 
including among others sponges, mollusks and tunicates.7-10 
Interestingly, in several cases staurosporine and related 
derivatives (Figure 1) were isolated from Streptomyces sp.11 
The occurrence of such compounds in E. vannamei 
may suggest the presence of associated microorganisms 
responsible for the biosynthesis of staurosporine and 
possible analogues. The LC-ESI-MS/MS technique is 
a useful tool for the analysis of secondary metabolites 
at low concentrations in biological samples.12,13 For this 
reason, it also constitutes a good analytical instrument in 
the identification of staurosporine and its derivatives from 
associated marine microorganisms. In order to determine 
chemical structures and their behavior in detail, it is important 
to define respective gas phase fragmentation reactions,14,15 
based on systematic parameters investigations16 and/or 
computational chemistry.17,18 Such experiments offer, for 
instance, better insights into respective fragmentation 
pathways and, by that also enable a more sensitive, as 
well as, selective detection of studied compounds. Taking 
into account the important biological activity observed for 
staurosporine,19,20 the present work aims at identification 
the possible producers of staurosporine derivatives among 
the microbiota recovered from E. vannamei. Furthermore, 
the occurrence and identification of staurosporine and 
derivatives from associated microorganisms shall be 
studied in detail by LC-MS/MS analysis supported by 
computational chemistry studies.
Experimental
Chemicals 
Staurosporine was acquired from Sigma Aldrich and 
hydroxy-7-oxo-staurosporine previously isolated from 
E. vannamei.5 For ESI-MS and ESI-MS/MS analysis the 
samples were prepared in methanol (HPLC grade) and 
glacial acetic acid purchased from J.T. Baker (Phillipsburg, 
NJ, USA). The water was purified with a Milli-Q system 
(Millipore, Bedford, MA, USA). Cell culture media, fetal 
bovine serum (FBS) and antibiotics were acquired from 
Gibco (Grand Island, NY). MTT reagent was obtained 
from Sigma Aldrich (St. Louis, MO, USA).
Collection of Eudistoma vannamei and isolation of 
associated bacteria
Specimens of Eudistoma vannamei were hand collected 
at Taiba Beach (03°30’21.23’S; 038°53’40.16’W), located 
on the northeastern coast of Brazil. Sampling was carried 
out with the slightest contamination possible, as the material 
was gathered and stored with sterile utensils. For isolation 
of microorganisms, the sample was homogenized in sterile 
seawater and aliquots of 20 mL were stroked onto Petri 
dishes containing different agar based media. The following 
media were used, supplemented with cycloheximide 
50 µg mL-1: SCA (Starch Casein Agar, HIMEDIA, prepared 
with distilled H2O) and AIA (Actinomycete Isolation Agar, 
HIMEDIA, prepared in 75% sea-water).
Purity of strains was resolved by sequential re-strikes 
onto new agar plates and pure strains then inoculated in 
fresh liquid medium for culture maintenance and up-scaled 
growth. Each culture with an isolated strain was sampled 
with liquid media into cryovials and supplemented with 
25% glycerol for storage at -70o C.
Scaled-up growth and extraction 
Pure strains were harvested from agar plates and 
inoculated in sterile 500 mL Erlenmeyer flasks with 100 mL 
of house-formulated broth containing 2% glucose, 1% 
starch, 1% hydrolyzed soy and 0.4% yeast extract in sea 
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Figure 1. Compounds monitored by LC-MS/MS in MRM mode.
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water. The flasks were left under 200 rpm agitation and 
28°C for 5 days. The broth was separated from the biomass 
by filtration and subsequently extracted with ethyl acetate. 
The solvents were evaporated under vacuum, thus, yielding 
two organic extracts for each isolated strain.
Screening for cytotoxicity 
Cytotoxic activity of extracts was evaluated against 
three human tumor cell lines obtained from the National 
Cancer Institute (Bethesda, MD, USA): MDA-MB-435 
(melanoma), SF-295 (CNS glioblastoma) and HCT-8 
(colon carcinoma). Cells were grown in RPMI-1640 
medium supplemented with 2 mmol L-1 glutamine, 10% 
fetal calf serum (FCS), 100 mg mL-1 streptomycin and 
100 U mL-1 penicillin at 37 °C in a 5% CO2 atmosphere. 
The cell cultures were regularly split to keep them in 
logarithmic growth phase.
At first, in a qualitative approach, the effect of 
100 µg mL-1 of each extract dissolved in DMSO on tumor 
cell viability was evaluated in vitro using the MTT assay.21 
Cells were incubated with extracts for 72 h in 96-well 
plates. At the end of the incubation period, the medium 
of each well was replaced by fresh media containing 
0.5 µg mL-1 of the MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide] (Sigma Aldrich Co., 
St. Louis, MO, USA) reagent and left for another 3 h. The 
cells were centrifuged and the supernatant then discarded. 
The generated formazan salt was diluted in DMSO and 
the absorbance detected with a multiplate reader (DTX 
880 Multimode Detector, Beckman Coulter, Inc. Fullerton, 
California, USA) at 570 nm. Those extracts considered 
active (that reduced cell viability by over 75%) were tested 
again in a serial dilution, with concentrations varying 
between 0.02 and 100 mg mL-1. Staurosporine (1 µg mL-1; 
2 mM) was used as positive control. In result of the detected 
cell viabilities, the 50% inhibitory concentration (IC50) was 
calculated, along with the respective 95% CI (confidence 
interval), by non-linear regression using the software 
GraphPad Prism 5.0 (Intuitive Software for Science, San 
Diego, CA).
Identification of bacteria: nucleic acid extraction, 16S rRNA 
gene amplification, and sequencing 
Genomic DNA extraction from the selected 
microorganism was carried out using a CTAB-based 
protocol.22 Concentration and quality of DNA extractions 
were measured using a Nanodrop Spectrophotometer ND-
1000 (NanoDrop, Wilmington, DE, USA). The 16S rRNA 
gene was partially amplified from genomic DNA by PCR 
using primers 63F (5’-CAG GCC TAA CAC ATG CAA 
GTC-3’) and 1389R (5’-GGG CGG WGT GTA CAA 
GGC-3’).23 Amplification reactions were performed in a 
final volume of 25 µL containing 100 ng of genomic DNA 
(template), 20 mmol L-1 Tris–HCl (pH 8.4), 50 mmol L-1 
KCl, 1.5 mmol L-1 MgCl2, 200 µmol L-1 of each nucleic 
acid (dATP, dCTP, dGTP and dTTP), 0.5 µmol L-1 of 
each primer and 1.0 units of Taq DNA Polymerase (MBI 
Fermentas Inc., USA). PCR reactions were carried out in a 
thermocycler (Eppendorf AG 22331; Eppendorf, Hamburg, 
GER) programmed for an initial denaturation step (4 min at 
94 °C) followed by 35 cycles of 1 min 94 °C, 1 min at 55 °C 
and 2 min at 72 °C. The last cycle was followed by a 10 min 
final extension at 72 °C. The specificity of amplifications 
was confirmed by 1% agarose gel electrophoresis stained 
with SYBR Safe DNA Gel Stain (Invitrogen, USA). PCR 
products were purified using Wizard SV Gel and PCR 
Clean-up System (Promega Corporation, Madison, WI, 
USA). 
DNA sequencing was performed by Macrogen 
Inc. (Seoul, Korea) using the ABI PRISM BigDyeTM 
Terminator Cycle Sequencing kit (Applied Biosystems, 
Foster City, CA, USA) following the protocols supplied 
by the manufacturer. The sequencing reactions were 
performed using the primers 63F, 1389R, 518F (5’-CCA 
GCA GCC GCG GTA ATA CG-3’) and 800R (5’-TAC 
CAG GGT ATC TAA TCC-3’). The fluorescent-labeled 
fragments were purified using an ethanol precipitation 
protocol, resuspended in distilled water and subjected 
to electrophoresis in an ABI 3730 sequencer (Applied 
Biosystems, Foster City, CA, USA). The nucleotide 
sequences were assembled, analyzed, and manually edited 
using the Sequencher software package (version 4.5; Gene 
Codes Co., Ann Arbor, MI) and compared to sequences 
within the NCBI database (http://www.ncbi.nlm.nih.gov/) 
using the Basic Local Alignment Search Tool (BLAST). 
The nucleotide sequence was submitted to NCBI GenBank 
and is available under the accession number JN703426.
HPLC-DAD-ESI-MS/MS and UPLC-MS/MS analysis 
Samples were injected into a HPLC system (Shimadzu-
LC 6AD) equipped with a Diode Array Detector 
(Shimadzu-SPD M10A). Routine detection was performed 
at 324 nm. The separation was profiled on a LC-column 
(Shimadzu-ODS-C18, 5 µm, 250 × 4 mm i.d.), using a 
MeOH/H2O system (with 1.0% acetic acid) as mobile 
phase. A linear gradient from 20% to 100% MeOH was 
applied in a period of 60 min. For HPLC-DAD-ESI-MS/MS 
analysis, the samples were injected into a HPLC system 
(Shimadzu-LC 20AD) equipped with a Diode Array 
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Detector (Shimadzu-SPD M20A). The separation was 
performed at the conditions previously established. 
High resolution electrospray ionization mass 
spectrometry (HR-ESI-MS) were acquired in positive ion 
mode and recorded on a hybrid quadrupole-time of flight 
instrument (UltrOTOF-Q, Bruker Daltonics, Billerica, 
MA). Conditions: capillary voltage 3400 V; dry gas 
temperature, 180 °C; dry gas flow, 4 L h-1 and nitrogen 
as nebulizer gas. Na+TFA (sodiated trifluoroacetic acid) 
10 mmol L-1 was used as standard for internal calibration.
Low Resolution Analyses were performed with a Waters 
Acquity™ (Milford, MA, U.S.A.) ultra performance liquid 
chromatography (UPLC) system, connected to a Acquity™ 
triple quadrupole mass spectrometer (QqQ). For the analysis 
a ACQUITY UPLC® BEH C18 column was used (1.7 µm 
pore size, 2.1 × 50 mm). The chromatographic conditions 
were as followed: 0.3 mL min-1 flow, 30 °C column and 20 °C 
sample temperature. The mobile phase used was MeOH/
H2O (with 1.0% acetic acid), applying a linear gradient 
from 20% to 100% of MeOH over 15 min. Fractions and the 
chemical reference staurosporine were diluted in MeOH to 
a concentration of 20 µg mL-1 and 10 µg mL-1, respectively. 
From each 5 µL were injected for analysis.
The analysis on QqQ was carried out in an electrospray 
ionization (ESI) source, in the positive mode. The source 
block and desolvation temperatures were kept at 150 °C 
and 250 °C, respectively. Nitrogen was used as both, 
drying and nebulizing gas and argon as collision gas. MS 
parameters were optimized by direct infusion of the chemical 
reference staurosporine. The transitions m/z 467 > 338 
and m/z 467 > 130 were monitored for staurosporine, 
m/z 497 > 368 and m/z 497 > 130 for hydroxy-7-oxo-
staurosporine, m/z 483 > 130 for hydroxy-staurosporine 
as well as m/z 481 > 352 and m/z 481 > 130 for 7-oxo-
staurosporine. Conditions for staurosporine were tuned to 
attain higher sensitivity and values transferred for transitions 
of the other derivatives. In summary, collision energy was 
set at 24 eV for transitions to the fragment at m/z 130 and 
at 18 eV for remaining transitions. The cone and capillary 
voltages were set at 36 V and 3.7 kV, respectively. Qualitative 
analysis of fractions and reference were performed by 
multiple reaction monitoring (MRM) of the protonated 
molecules ([M+H]+) and their corresponding ions with a 
well time of 0.025 s. For this purpose the MassLynx data 
sampling software (Waters), version 4.1, was employed.
Computational methods
All molecules had their geometries optimized by 
applying the BP86/6-31+G(d,p)24,25 model interfaced 
with Gaussian 03 software.26 The minimum at potential 
energy surface was indicated by analysis of the harmonic 
frequencies. Protonation sites were indicated by analyzing 
the molecular electrostatic potential map (MEP) and proton 
affinities (PA), which were obtained through calculation 
of the enthalpies values for protonated and neutral species 
following the equation: M + H+ → MH+. All molecules 
were visualized at Molekel 5.0 software.27
Results and Discussion
Eighty four colonies were recovered from E. vannamei 
of which 17 were elected for bioactivity evaluation on 
tumor cells, 6 isolated in AIA and 11 in SCA media. In the 
qualitative screening, it was noticeable that broth extracts 
were generally more cytotoxic than those from remaining 
biomass (Figure 2). Furthermore, the ethyl acetate extract 
derived from EVA 01063 was clearly the most active among 
the tested strains, reducing viability of all cell lines by over 
75%. IC50 for the ethyl acetate extract of EVA 01063 was 
quite low, ranging from 0.75 to 1.30 mg mL-1, whereas, 
the methanol extract ranged between 22 and 79 mg mL-1 
(Table 1). BLAST analysis of the 16S sequence obtained 
for EVA 01063 determined that this strain belonged, indeed, 
to the Streptomyces genus. 
Crude ethyl extracts of the selected Streptomyces 
strain were analyzed by HPLC-ESI-MS. The HR-ESI-MS 
spectra were acquired in positive ion mode and the results 
are present at Figure S1 (see Supplementary Information). 
The analysis of hydroxy-7-oxo-staurosporine in the extracts 
applying TOF analyzer was not conclusive. The UV 
chromatogram may suggest the presence of the cytotoxic 
compounds at minor concentrations; but, in this particular 
case, the TOF analyzer could not provide confident 
results for the presence or absence of hydroxy-7-oxo-
staurosporine. Nevertheless, a systematic investigation 
of the gas phase fragmentation reactions of protonated 
staurosporine (a possible precursor of hydroxy-7-oxo-
staurosporine) was performed, applying for this purpose 
Q-TOF and QqQ analyzers. These data are important to 
define strategies for multiple reaction monitoring (MRM) 
and/or neutral loss experiments in QqQ devices, which 
increase the sensitivity and are an excellent tool to analyze 
metabolites at low concentration in biological samples.28
Our research group has studied heterocyclic alkaloids 
in order to understand the fragmentation mechanism for 
these compounds under collision.29 Thus, on the basis of 
the observation, the initial step for the fragmentation studies 
was to define the possible protonation sites.17,18 In order 
to identify these regions in staurosporine derivatives, the 
proton affinities (PA) and molecular electrostatic potential 
map (MEP) calculations were done and all the compounds 
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showed the same behavior, Figure 3. The most basic regions 
(nucleophilic) in the MEP are indicated by red color 
(using the staurosporine and hydroxy-7-oxo staurosporine 
models), showing that the possible protonation sites are 
the nitrogen and oxygen atoms in the molecule (Figure 3). 
The PA values for these possible protonation sites (Table 
2) were obtained as described at the experimental section. 
The most stable protonation site is indicated by the highest 
value of PA. In this case, the nitrogen (2) and the oxygen (4) 
atoms are the most probable protonation site, respectively 
(Table 2). These results are useful to understand the 
reactivity under collision-induced dissociation (CID) 
conditions for these compounds. Protonation in O(4) 
indicates that the reactivity of staurosporine derivatives 
may be compared to the lactam rings, where the proton is 
located at carbonyl.30
Thus, on the basis of these two possible protonation 
sites and PA values, two main competitive fragmentation 
pathways were suggested from the protonated molecule 
of the staurosporine derivatives (for fragment ions spectra 
see Figure 4). The most stable protonated specie occurs 
when the proton take place at N(2) (Table 2) and, pathway 
A (Figure 5) triggers by a concerted mechanism. In this 
case, the protonation site is fundamental for this reaction 
and the proton migration produces the ion at m/z 130 (see 
Figure 5). The m/z 130 can eliminate a ketene affords the 
final ion at m/z 88. Both ions have the same mass values 
for all analyzed staurosporine derivatives and present the 
best choice for MRM analysis.
Figure 2. Single dose (100 µg mL-1) cytotoxic activity of ethyl acetate extract from broth (dark gray) and methanol extract from biomass (light gray) of 
selected bacterial strains recovered from E. vannamei evaluated against HCT-8, MDA-MB-435 and SF-295 cell lines by the MTT assay after 72 h incubation. 
Staurosporine (STP, 1 µg mL-1) was used as positive control. Data obtained from two independent experiments (n = 3) are presented as a percentage of 
cell viability inhibition relative to untreated cells (100%). 
Table 1. Cytotoxic activity of extracts obtained from strain EVA 01063 
recovered from E. vannamei. Broth and biomass extracts were tested on 
HCT-8, MDA MB-435 and SF-295 cell lines and evaluated by the MTT 
assay after 72h incubation. Staurosporine was used as positive control
Sample HCT-8 MDA MB-435 SF-295
Broth 
(ethyl acetate)
0.97a
(0.79 - 1.19)
1.30a
(0.91 - 1.84)
0.75a
(0.63 - 0.89)
Biomass 
(methanol)
34.20a
(25.03 - 46.73)
79.57a
(68.00 - 93.12)
22.39a
(18.67 - 26.86)
Staurosporine 0.04a
(0.03 - 0.05)
0.10a
(0.07 - 0.14)
0.27a
(0.21 - 0.34)
aIC50 [µg mL-1] values and their respective 95% confidence intervals (values 
in brackets) were obtained by nonlinear regression on the GraphPad Prism 
5.0 software (Intuitive Software for Science, San Diego, CA).
Figure 3. Molecular electrostatic potential map (MEP) for staurosporine 
and hydroxy-7-oxo-staurosporine.
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Table 2. Proton affinity values (PA) and relative enthalpies (DH298), in kcal mol-1, for hydroxy-7-oxostaurosporine (for the respective atom number, number 
between parenthesis, see Figure 1), obtained by BP86/6-31+G(d,p) model
Atom (1) (2) (3) (4) (5) (6) (7)
PA 219.1 230.8 210.6 221.4 197.1 186.3 195.3
DH298 11.8 0 20.3 9.4 33.7 44.5 35.6
Figure 4. Mass spectra from ESI-MS/MS analysis of hydroxy-7-oxostaurosporine (A) and staurosporine (B).
O
O
N
H
m/z 130
m/z = 467
R1=R2= H
OR1=     R2= OH
m/z = 497
neutral loss
O
N
H
m/z 88
H2C C O
neutral loss
A
O
N
O
m/z = 467
R1=R2= H
OR1=     R2= OH
m/z = 497
m/z = 338
R1=R2= H
OR1=     R2= OH
m/z = 368
neutral loss
B
O NN
H
N O
O
HN
R1
H
R2
O NN
H
N OH
O
N
R1
H
R2
NN
H
H
N OR1
R2
NN
H
H
N OHR1
R2
Figure 5. Major fragment ions observed and their corresponding fragmentation mechanisms for staurosporine derivatives.
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Figure 6. UPLC-MS/MS analysis in MRM mode of staurosporine (standard) and the selected extract (EVA 01063) from the Streptomyces sp. Respective 
m/z transitions are indicated in the MS spectra. X-axis: min; Y-axis: relative signal intensity.
Pathway B occurs when proton take place in O(4) 
(lactam ring) through a charge remote mechanism by a 
neutral elimination, which similar to the ones observed 
from other marine natural products,21 exhibiting ions at 
m/z 338 and 368 for staurosporine and hydroxy-7-oxo-
staurosporine, respectively (Figure 5). The ion at m/z 338 
can fragment, by a ring contraction, to form the ion of the 
m/z 295. The low intensity of this ion is in agreement of the 
low stability observed for three membered rings, and the 
second carbonyl function of hydroxy-7-oxo-staurosporine 
completely inhibits the ring contraction mechanism. 
Four channels of protonated molecules were selected 
to perform the MRM analysis of the compound described 
in Figure 1. In a preliminary analysis the reference 
staurosporine was used at 10 µg mL-1 to verify the detection 
capacity of the UPLC-ESI-MS/MS method and to optimize 
MS settings for the MRM analysis. Tuning experiments 
performed by direct infusion at 36 V cone energy and 20 eV 
collision energy, exhibited the priory described fragments 
for staurosporine (Figure 5B), showing the protonated 
molecule [M+H]+ at m/z 467.3 and the correspondent 
fragments at m/z 338.18, 285.5, 130.1 and 88.1. The 
MRM analysis evidenced that the selected strain (01063) 
accumulates staurosporine and does not accumulate or 
generate the derivatives 7-oxo-staurosporine, hydroxy-7-
oxo-staurosporine and hydroxy-staurosporine.
Conclusions
The electrospray ionization mass spectrometric 
analysis of extracts from the isolated Streptomyces strain 
01063 demonstrated the presence of staurosporine, 
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but none of the derivatives.. These results suggest 
that microorganisms associated to E. vannamei are 
responsible for the accumulation and possibly also for 
the biosynthesis of staurosporine, which has already 
been reported for other Streptomyces spp. The isolation 
of staurosporine derivatives, such as hydroxy-7-oxo-
staurosporine, from E. vannamei extracts, therefore, 
indicates that staurosporine was oxidized after secretion 
by the associated microorganisms, for instance, on their 
cell surface or surrounding environment. Alternatively, it 
could suggest that this sequential reaction of staurosporine 
in the extracellular medium just does not occur under the 
performed Streptomyces sp. cultivation conditions. On the 
other hand, metabolization of staurosporine by the marine 
invertebrate itself should also be considered. Further 
studies are necessary to clarify in which way derivatives, 
such as the hydroxy-7-oxo-staurosporine, affect the known 
cytotoxic activity of staurosporine. 
Supplementary Information
Supplementary data are available free of charge at 
http://jbcs.sbq.org.br as a PDF file.
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